BAUSCH & LOMB CORP

Company Overview

Bausch + Lomb is a fully integrated global eye‑health company operating across Vision Care (≈57% of 2024 revenue), Pharmaceuticals (≈25%) and Surgical (≈18%), with a ~400‑product portfolio that includes consumer eye care, contact lenses, prescription ophthalmics (e.g., XIIDRA, MIEBO) and surgical systems/IOLs. The company generated $4.79B in 2024 revenue, sells in ~100 countries through a large direct commercial force and distributors, and manufactures at 23 facilities while outsourcing ~37% of product sales. Operational priorities center on new product launches (Lumify, SiHy Daily, premium IOLs), an active R&D pipeline, and inorganic growth via acquisitions, while key risks include regulatory approvals, loss of exclusivity, supply‑chain single‑source suppliers and high leverage. Bausch Health Companies Inc. remains the controlling shareholder (~88% as of Feb 2025), and a possible further separation or sale by the parent is under consideration.

Executive Compensation Practices

Given the business mix and 10‑K/10‑Q disclosures, compensation is likely structured around a mix of base salary, annual cash incentives tied to commercial performance (revenue, product volumes, net realized pricing/contribution), and long‑term equity (RSUs, performance shares/PSUs) tied to multi‑year metrics such as adjusted EBITDA, free cash flow/deleveraging, TSR and strategic milestones (product approvals, successful launches, and M&A integration). Management already cites acquisition contributions, gross‑to‑net trends (rebates/chargebacks), and margin expansion as primary performance drivers, so pay plans will commonly rely on adjusted (non‑GAAP) measures that exclude acquisition amortization and one‑time items; R&D and regulatory milestones may also be payout levers for Pharma & Surgical executives. High leverage and near‑term refinancing needs mean short‑ and long‑term incentives may emphasize cash generation, working capital, and debt reduction targets, while the controlling parent ownership and potential separation create a likelihood of retention/transaction bonuses and board/parent influence on pay outcomes and performance targets.

Insider Trading Considerations

Insider trading activity should be interpreted in light of heavy parent ownership (limited free float) and typical affiliate trading restrictions—material sales or purchases by Bausch Health could signal strategic moves (separation/sale) and materially affect market perception. Company‑specific catalysts that tend to trigger insider trades or regulatory blackout periods include quarterly earnings, FDA/EMA approvals or setbacks, product launches (Lumify, SiHy Daily, MIEBO/XIIDRA dynamics), recall or vendor issues (enVista recall), and major refinancing or acquisition announcements. Expect executives to use 10b5‑1 plans or pre‑approved trading windows to manage tax liabilities from equity vesting; also monitor for clustered insider sales after equity grants, and for disclosures tied to adjusted metrics (gross‑to‑net, adjusted EBITDA) since those non‑GAAP adjustments often drive incentive outcomes and related insider behavior. Finally, because the sector is highly regulated (FDA, EU MDR, reimbursement regimes), insiders will be tightly constrained around material non‑public regulatory or safety information.